An integrated pharmacokinetic-pharmacodynamic model is suggested for remoxipride and
its effect on prolactin (PRL) release acting by preventing the inhibitory effect of dopamine D2 …

1. The pharmacokinetics of remoxipride, a new neuroleptic, were investigated in 15 healthy
subjects after an intravenous infusion of 50 mg, an intramuscular injection of 100 mg and …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Prolactin response is a common
side effect of antipsychotic drugs. • The pool model was proposed to describe the effect of …

… 1989b; Wahlen et al. 1988) and single doses of other neuroleptics (Movin-Osswald et al.
1991; von Bahr et al. 199Ib). This similarity in Cmax,PRL between different neuroleptics and dif…

… for about 25% of the dose in subjects with normal renal function (Movin-Osswald et … of
determination was 0.1 g 1-F (2.4 ,umol 1-1). Normal values are between 0.3 and 1.0 g l-1. …

1. The prolactin response following administration of the D2‐dopamine receptor antagonist
remoxipride was studied in eight healthy male volunteers. The purpose of the study was to …

… in male volunteers (Farde et al. 1989; Movin-Osswald et al. 1992), as compared with other
… where longer durations were reported (Movin-Osswald et al. 1991; Von Bahr et al. 1991). …

… Single doses of the ER capsule have been administered to healthy volunteers (Movin-Osswald
et al. 1992), and pharmacokinetic simulations based upon these data suggest that the …

The tolerability and pharmacokinetics of raclopride extended release (ER) capsules have
been evaluated after a single oral dose and at steady state, with 3 different daily doses in 4 …

The pharmacokinetics and the influence on the prolactin (PRL) release of remoxipride,
raclopride and sulpiride were characterised. The impact of rate of administration and dosing …